Fig. 5 | Signal Transduction and Targeted Therapy

Fig. 5

From: Epidemiological and phylogenetic characteristics of human metapneumovirus in Beijing, China, 2014–2024

Fig. 5

a Positivity rates of hMPV across the four age groups in 2024. b Monthly distribution of different subgenotypes in Beijing, January–December 2024. c Age distribution of different subgenotypes in Beijing, Jan–Dec 2024. d Distribution of clinical diagnoses according to the dominant genotypes in Beijing, 2014–2024. B2 represents subgenotype B2 in 2014–2023; B2 (2024) represents subgenotype B2 in 2024. URTI upper respiratory tract infection, nsCAP non-severe community-acquired pneumonia, sCAP severe community-acquired pneumonia. N, the total number of hMPV-positive specimens successfully sequenced

Back to article page